Latent period for malignant mesothelioma of occupational origin.
about
Asbestos-induced peritoneal mesothelioma in a construction worker.Perspectives on refractory ceramic fiber (RCF) carcinogenicity: comparisons with other fibersPopulation Attributable and Preventable Fractions: Cancer Risk Factor Surveillance, and Cancer Policy ProjectionFactors that impact susceptibility to fiber-induced health effectsCurrent issues in malignant pleural mesothelioma evaluation and managementLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesMalignant mesothelioma mortality - United States, 1999--2015Mesothelioma and asbestosis in a young woman following occupational asbestos exposure: Short latency and long survival: Case Report.BTS statement on malignant mesothelioma in the UK, 2007.Malignant vascular tumours of the pleura in "asbestos" workers and endothelial differentiation in malignant mesothelioma.Mesothelioma in a community in the north of England.Pleural and peritoneal mesotheliomas in the Friuli Venezia Giulia register: data analysis from 1995 to 2015 in Northeastern Italy.Malignant pleural mesothelioma: a single-center experience in Turkey.The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad.Comment on 'The latency period of mesothelioma among a cohort of British asbestos workers (1978-2005)': the effect of left censoring.Reliability of Family Proxy Data for Studies of Malignant Mesothelioma: Results from the ATSDR Pilot Surveillance.Case report: peritoneal mesothelioma from asbestos in hairdryers.Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.Changing trends in US mesothelioma incidenceMalignant mesothelioma in south east England: clinicopathological experience of 272 casesMalignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy.Assessment of Residential History Generation Using a Public-Record Database.Distinctive clinical characteristics of malignant mesothelioma in young patients.Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509Malignant peritoneal mesothelioma in a pediatric patient mimicking inflammatory bowel disease.Malignant pleural mesothelioma in a 17-year old boy: A case report and literature review.The proliferative effects of asbestos-exposed peripheral blood mononuclear cells on mesothelial cells.Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma.Medical monitoring of asbestos-exposed workers: experience from Poland.The latency period of mesothelioma among a cohort of British asbestos workers (1978-2005)Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasiaManagement of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033.Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug.Oncolytic Viral Therapy for Mesothelioma.Epidemiology and trend analysis on malignant mesothelioma in China.Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma.
P2860
Q24811903-AFC88660-036A-4035-A840-D3342A327619Q28383101-E932BD8D-7915-40BA-9118-9BBA20532A87Q28386929-788E0F5B-024E-4912-8F23-BA31909AD159Q28389535-37172A65-B903-447B-A0B0-8A8651CBCA42Q28393560-CF2BB385-330B-46F8-8A54-B0C545CB3634Q28395597-A74E5174-F051-4DFD-AA50-FC123FAE4939Q28950535-A436584B-7EF3-44FE-8CD4-8A9636CD1B10Q30477968-6D54503B-643E-48A1-8635-08B862025D33Q30478994-4C27548C-B90E-41BB-AB13-A5B16831B163Q33389635-D7754A98-1415-4FCB-B34D-2FC7391D84C5Q33391395-210C9609-9D21-4C1F-82B9-8DF0B0BB30A3Q33639232-862714BE-6220-4EF6-AC8C-89B2B3C0FDE2Q33686248-03622B4F-571D-4AE2-BA84-551B1FA3E543Q33871638-08A86028-14B1-470D-9930-4B006EE34675Q34658218-BBBAC689-438A-4EB7-ACB4-284890B6DD38Q34680445-43413C3E-47D1-40A1-ADAA-8BD28E0D8A52Q34754477-C4E1218B-ADE7-470E-AC94-554102DDFE24Q34917972-322CF6B5-A2A9-49F3-B62C-C8992F3A2670Q35501138-8F9CA656-8A14-4D3F-9FAC-47768A8DAA3CQ35563609-32C30490-B710-4488-8F14-1C68F71F9A17Q35623638-692B62DE-CD2A-4A4B-973E-F64768859F4CQ36102588-1E15CF29-65AA-46B5-B3BC-75CEE9B82E6BQ36140968-7785674C-A0D1-445D-93F3-1FE52E81E1DBQ36337646-16DEF388-B2F0-43EB-B096-7AB999F681BDQ36427919-342FDED1-BE08-4A08-B5A2-818D88ACBB22Q36766690-B8ABBE20-D2BD-4368-94A1-7DDBA0A0AE84Q36825187-693FB7AC-A8DD-4F54-A6EB-CB55C4CE02C0Q36889671-BFD445D6-3CA0-4E19-A145-B705E59AA44EQ37145180-ED4EE9AF-D930-41CF-925A-E97AD24D0FB1Q37214282-6ED883C0-ADF7-45ED-9139-106EF7A583F1Q37239751-E353BE0C-179A-4465-8D0B-00C98CBCA293Q37277451-56373180-1D95-4FA1-9ACE-453CFA3A7CD0Q37507415-3D27EC30-0974-4CFD-B5BD-7A788D30F21FQ37537109-EF491C3B-239E-4E55-B550-D4851295C0D1Q38619843-9BD25738-9FCA-4D49-8182-11E36FB74486Q38985236-F2BA9F46-FBDE-41CC-96D8-B1BBEC53713AQ39104716-2F6F8D48-40AC-415A-9F95-38422A2F25C5Q40051845-5848E797-F597-4A5B-8CA9-D87EC619C46BQ41662375-2BC2DF30-2CD9-43A9-8DF8-9389D02F0346Q42131424-82021C9D-2344-49AF-A44D-AC66C937A7EC
P2860
Latent period for malignant mesothelioma of occupational origin.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Latent period for malignant mesothelioma of occupational origin.
@ast
Latent period for malignant mesothelioma of occupational origin.
@en
Latent period for malignant mesothelioma of occupational origin.
@nl
type
label
Latent period for malignant mesothelioma of occupational origin.
@ast
Latent period for malignant mesothelioma of occupational origin.
@en
Latent period for malignant mesothelioma of occupational origin.
@nl
prefLabel
Latent period for malignant mesothelioma of occupational origin.
@ast
Latent period for malignant mesothelioma of occupational origin.
@en
Latent period for malignant mesothelioma of occupational origin.
@nl
P1476
Latent period for malignant mesothelioma of occupational origin.
@en
P2093
Buncher CR
Lanphear BP
P304
P577
1992-07-01T00:00:00Z